Skip to search formSkip to main contentSkip to account menu

ABR-214936

National Institutes of Health

Related topics

Related topics

2 relations

Broader (2)

EnterotoxinsMembrane Glycoproteins

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2007
2007
A phase II study of a 5 T 4 oncofoetal antigen tumour-targeted superantigen ( ABR-214936 ) therapy in patients with advanced renal cell carcinoma
In a phase II study, 43 renal cell carcinoma patients were treated with individualised doses of ABR-214936; a fusion of a Fab… 
2006
2006
An open label phase I study of ABR-217620, a fusion protein of the 5T4 antibody moiety and an engineered superantigen, in patients with non-small cell lung, renal cell or pancreatic cancer.
3083 Background: ABR-217620 (naptumomab estafenatox) is a recombinant fusion protein that consists of the 5T4Fab moiety… 
2004
2004
A phase II study of ABR-214936 (anatumomab mafenatox) tumour targeted superantigen (TTS) therapy in patients with advanced adenocarcinoma of the pancreas.
3162 Tumour Targeted Superantigen therapy is a novel form of cancer therapy. The principle involves targeting the superantigen… 
2004
2004
A phase II study of ABR-214936 (anatumomab mafenatox) tumour targeted superantigen (TTS) therapy in patients with advanced adenocarcinoma of the pancreas
3162 Tumour Targeted Superantigen therapy is a novel form of cancer therapy. The principle involves targeting the superantigen… 
2003
2003
1099 A phase II study of ABR-214936 (anatumomab mafenatox) tumour targeted superantigen (TTS) therapy in patients with advanced renal cell carcinoma (RCC)
2003
2003
O-151 Phase II study of anatumomab mafenatox (ABR-214936) in advanced NSCLC: Results of a multi-institutinal open label repeat dose trial with patient-specific dose escalation
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)